JP2012520081A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520081A5
JP2012520081A5 JP2011554211A JP2011554211A JP2012520081A5 JP 2012520081 A5 JP2012520081 A5 JP 2012520081A5 JP 2011554211 A JP2011554211 A JP 2011554211A JP 2011554211 A JP2011554211 A JP 2011554211A JP 2012520081 A5 JP2012520081 A5 JP 2012520081A5
Authority
JP
Japan
Prior art keywords
tumor
polypeptide
seq
angiogenesis
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011554211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520081A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027041 external-priority patent/WO2010105097A2/en
Publication of JP2012520081A publication Critical patent/JP2012520081A/ja
Publication of JP2012520081A5 publication Critical patent/JP2012520081A5/ja
Pending legal-status Critical Current

Links

JP2011554211A 2009-03-11 2010-03-11 Sparc血管新生ドメイン及び使用方法 Pending JP2012520081A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15932209P 2009-03-11 2009-03-11
US61/159,322 2009-03-11
PCT/US2010/027041 WO2010105097A2 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Publications (2)

Publication Number Publication Date
JP2012520081A JP2012520081A (ja) 2012-09-06
JP2012520081A5 true JP2012520081A5 (cg-RX-API-DMAC7.html) 2013-05-02

Family

ID=42729116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554211A Pending JP2012520081A (ja) 2009-03-11 2010-03-11 Sparc血管新生ドメイン及び使用方法

Country Status (13)

Country Link
US (2) US20120087910A1 (cg-RX-API-DMAC7.html)
EP (1) EP2405932A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012520081A (cg-RX-API-DMAC7.html)
KR (2) KR20130043242A (cg-RX-API-DMAC7.html)
CN (2) CN102482334A (cg-RX-API-DMAC7.html)
AU (1) AU2010224031B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1009457A2 (cg-RX-API-DMAC7.html)
CA (1) CA2755109A1 (cg-RX-API-DMAC7.html)
IL (2) IL215089A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011009478A (cg-RX-API-DMAC7.html)
NZ (1) NZ595528A (cg-RX-API-DMAC7.html)
WO (1) WO2010105097A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107415B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544704A4 (en) * 2010-03-11 2013-08-28 Abraxis Bioscience Llc SPARC ANGIOGENIC DOMAIN AND METHODS OF USE
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN120361186B (zh) * 2025-04-15 2025-12-30 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
WO2008000079A1 (en) * 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法

Similar Documents

Publication Publication Date Title
Wood et al. Molecular histology of lung cancer: from targets to treatments
JP2012521768A5 (cg-RX-API-DMAC7.html)
Zhang et al. Silencing of LncRNA HULC enhances chemotherapy induced apoptosis in human gastric cancer
Friedländer et al. ErbB-directed immunotherapy: antibodies in current practice and promising new agents
HRP20231525T1 (hr) Postupci i pripravci za dijagnozu i liječenje raka
US11904057B2 (en) Nanoparticle-hydrogel composite for nucleic acid molecule delivery
Kutova et al. The multifaceted role of connexins in tumor microenvironment initiation and maintenance
WO2006121991A3 (en) Compositions and methods for detection, prognosis and treatment of breast cancer
JP2013532126A5 (cg-RX-API-DMAC7.html)
CA2648118A1 (en) Methods using sparc for predicting the response of a tumour to chemotherapy agents
JP2009523739A5 (cg-RX-API-DMAC7.html)
RU2016140214A (ru) Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц
JP2013505232A (ja) 癌治療のための薬剤標的としてのFra−1標的遺伝子
CN109468326A (zh) 一种cd4+t核酸适配体及其应用
CN105859841B (zh) 一种双靶向嵌合肽及其在制备抗肿瘤转移药物中的应用
JP2005520543A5 (cg-RX-API-DMAC7.html)
ES2398391T3 (es) Polinucleótidos relacionados con cáncer de colon
JP2009523004A5 (cg-RX-API-DMAC7.html)
US9545417B2 (en) Methods of inhibiting cancer stem cells with HMGA1 inhibitors
Xiao et al. MicroRNA-119 Inhibitor-Loaded Nanoparticles Improve Non-Small Cell Lung Cancer and Suppress Metastasis Through Up-Regulation of Autophagy-Related Proteins
EP3004153A1 (en) Recombinant cancer therapeutic cytokine
Hu et al. Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma
JP2013505268A5 (cg-RX-API-DMAC7.html)
Kosmidis et al. Gene therapy for hepatocellular carcinoma: An update
Xu et al. LncRNA SOX21‐AS1 Promotes the Progression of Pancreatic Cancer by Sponging miR‐9‐3p and Upregulating YOD1